Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Brain and Central Nervous System Tumors
Interventions
Ad5CMV-p53 gene, conventional surgery
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Conditions
Glioma, Brain Tumor, Glioblastoma Multiforme, GBM, Gliosarcoma, GS
Interventions
lapatinib ditosylate, Adjuvant therapy, Conventional surgery, Neoadjuvant therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, temozolomide
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Summit, New Jersey
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
Interventions
Interferon-beta
Genetic
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 2 more
Conditions
Brain and Central Nervous System Tumors
Interventions
bispecific antibody MDX447, lymphokine-activated killer cells, conventional surgery
Biological · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions
ZD6474 (Vandetanib), Carboplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Brain and Central Nervous System Tumors
Interventions
procarbazine hydrochloride, thalidomide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
5
States / cities
Decatur, Illinois • Goldsboro, North Carolina • Winston-Salem, North Carolina + 2 more
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions
PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Conditions
Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma, Recurrent Grade IV Glioma, Adult Anaplastic Oligodendroglioma, Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor, Adult Anaplastic Oligoastrocytoma, Recurrent High Grade Glioma
Interventions
flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-Tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, E. coli CD-expressing genetically modified neural stem cells
Drug · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
13 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Duarte, California
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
aminolevulinic acid, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Michael Vogelbaum, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Brain and Central Nervous System Tumors
Interventions
gefitinib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
iodine I 131 monoclonal antibody 3F8
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Phase 1 Interventional Results available

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

NCT04477200
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
Interventions
Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 2 Interventional Results available

Dose-Intense Temozolomide in Recurrent Glioblastoma

NCT00657267
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide
Drug
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
6
States / cities
Boston, Massachusetts • Lebanon, New Hampshire • Winston-Salem, North Carolina + 1 more
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions
DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8
Genetic · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Brain and Central Nervous System Tumors
Interventions
conventional surgery, iodine I 131 monoclonal antibody 81C6, radiation therapy
Procedure · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
Atezolizumab, Cabozantinib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, paclitaxel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma
Interventions
ritonavir, lopinavir
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Brain and Central Nervous System Tumors
Interventions
karenitecin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Conditions
Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
Interventions
HSPPC-96, bevacizumab
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
417
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 268 more
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temodar and O6-Benzylguanine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina